-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Qs25xlUfoqM+6DwNAbXc/XbqL4vl6oCgyML5OmeeLInC/ZmxNci0OcpgotCFt1Bi oC0jj1p+ewxZ+m7IxjgwjA== 0001209191-08-067409.txt : 20081229 0001209191-08-067409.hdr.sgml : 20081225 20081229093612 ACCESSION NUMBER: 0001209191-08-067409 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20081223 FILED AS OF DATE: 20081229 DATE AS OF CHANGE: 20081229 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BARR PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000010081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221927534 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 BUSINESS PHONE: 201-930-3300 MAIL ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 FORMER COMPANY: FORMER CONFORMED NAME: BARR LABORATORIES INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SEAVER PETER CENTRAL INDEX KEY: 0001237271 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09860 FILM NUMBER: 081271174 BUSINESS ADDRESS: STREET 1: BARR LABORATORIES INC STREET 2: 300 CORPORATE DRIVE SUITE 10 CITY: BLAUVELT STATE: NY ZIP: 10913 BUSINESS PHONE: 18002275227 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2008-12-23 1 0000010081 BARR PHARMACEUTICALS INC BRL 0001237271 SEAVER PETER BARR PHARMACEUTICALS, INC. 400 CHESTNUT RIDGE ROAD WOODCLIFF LAKE NJ 07677 0 1 0 0 Insider Non-Qualified Stock Options 57.35 2008-12-23 4 D 0 10000 D 2006-11-03 2015-11-03 Common Stock 10000 0 D Non-Qualified Stock Options 54.25 2008-12-23 4 D 0 5000 D 2008-05-17 2017-05-17 Common Stock 5000 0 D These options were assumed by Teva Pharmaceutical Industries Ltd pursuant to a merger agreement between the Issuer and Teva and replaced with options to purchase 15,812 shares of Teva Common Stock for $36.27 per share. These options were assumed by Teva Pharmaceutical Industries Ltd pursuant to a merger agreement between the Issuer and Teva and replaced with options to purchase 7,906 shares of Teva Common Stock for $34.31 per share. /S/ William T. McKee as Attorney-in-Fact for Peter Seaver 2008-12-29 -----END PRIVACY-ENHANCED MESSAGE-----